We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The U.S. Supreme Court this week opted not to take up a patent suit between Vanda Pharmaceuticals and generic drugmaker Hikma Pharmaceuticals over Vanda’s schizophrenia treatment Fanapt (iloperidone). Read More
Republicans on the House Energy and Commerce Committee on Tuesday revived their investigation into the role three drugmakers played in the opioid crisis, pressing Insys, Mallinckrodt and Purdue Pharma for more details. Read More
Three acute treatments for migraine — Eli Lilly’s Reyvow (lasmiditan), Biohaven’s rimegepant, and Allergan’s Ubrelvy (ubrogepant) — may not be cost-effective, according to the Institute for Clinical and Economic Review (ICER). Read More